Erlotinib or Radiotherapy in the Treatment of Brain Metastasis from EGRF-Mutant NSCLC?

References (1)

1. . Arbour KC, Kris MG, Riely GJ, et al. Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases. Cancer 2018;124:105-9. [CrossRef] 2. Magnuson WJ, Lester-Coll NH, Wu AJ, et al. Management of brain metastases in tyrosine kinase inhibitor-naïve epidermal growth factor receptor-mutant non-small-cell lung cancer: a retrospective multi-institutional analysis. J Clin Oncol 2017;35:1070-7. [CrossRef] 3. Zhang Q, Zhang X, Yan H, Jiang B, Xu C, Yang J, Chen Z, Su J, Wu YL, Zhou Q. Effects of epidermal growth factor receptortyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis. Thorac Cancer 2016;7:648- 54. [CrossRef] 4. Eisenhauer EA, Verweij J. New response evaluation criteria in solid tumors: RECIST GUIDELINE VERSION 1.1. EJC Suppl 2009;7:5. [CrossRef] 5. Linardou H, Dahabreh IJ, Kanaloupiti D, et al. Assesment of somatic k-ras mutationsas a mechanism associated with resistance to EGFR-targetted agents: a systematic review and metaanalysis of studies in advanced non-small cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008;9:962-72. [CrossRef] 6. Zheng MH, Sun HT, Xu JG, Yang G, Huo LM, Zhang P, Tian JH, Yang KH. Combining whole-brain radiotherapy with gefitinib/ erlotinib for brain metastases from non-small-cell lung cancer: a meta-analysis Biomed Res Int 2016;2016:5807346. [CrossRef] 7. Ulahannan D, Lee SM. Erlotinib plus concurrent whole-brain radiation therapy for non-small cell lung cancers patients with multiple brain metastases. Transl Lung Cancer Res 2016;5:208- 11. [CrossRef]